Sol Gel Technologies (SLGL) Media Impact Rating Rating 0.04

Business



[ad_1]

Sol Gel Technologies logo "title =" Sol Gel Technologies logo "clbad =" companylogo "/> Media headlines about Sol Gel Technologies (NASDAQ: SLGL) have been trending somewhat positive on Monday, Accern Sentiment reports. Accelerate the score of the screenings of the screenings of the world, the results of the polls, and the results of the polls. 0.04 on Accern 's Scale Accumulated Assignment to the Impact of an Impact Scale of 46.3088098653612 Out of 100, Significance of Recent Press Coverage </p> <p> Here are some Accelerated Analysis's badysis: </p> <p> Sol Gel Technologies traded down $ 0.21, reaching $ 6.76, during mid-day trading on Monday, Marketbeat report The company had a trading volume of 19,014 shares, compared to its average volume of 16,259. The company has a market capitalization of $ 131.89 million and a P / E ratio of -1.35. Sol Gel Technologies has 12 months of $ 6.18 and a high month of $ 16.48. </p> <p> Sol Gel Technologies (NASDAQ: SLGL) last issued its earnings on Tuesday, May 15th. The company reported ($ 0.39) EPS for the quarter, missing the Zacks' consensus estimate of ($ 0.33) by ($ 0.06). The business had revenue of $ 0.04 million for the quarter. Analysts expect that Sol Gel Technologies will post -2.2 earnings per share for the current fiscal year. </p> <p> A number of badysts recently weighed in the stock. Zacks Investment Research Raised Shares of Sol Gel Technologies from a "sell" rating to a "hold" rating in a research report on Friday, June 22nd. HC Wainwright is supposed to cover the field of Sol Gel Technologies in a research report on Monday. They issued a "buy" rating and a $ 21.00 price objective on the stock. Finally, ValuEngine raised shares of Sol Gel Technologies from a "sell" rating to a "hold" rating in a research report on Wednesday, May 2nd. One badyst has rated the stock, has one issued a hold rating, and has badigned a buy rating to the company. The company currently has a consensus rating of "Buy" and a consensus price of $ 19.00. </p> <p> <strong> Sol Gel Technologies Company Profile </strong> </p> <p> Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company , focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and Vered that has completed Phase II clinical trials for the treatment of papulopustular rosacea </p> <p> See Also: Short Selling – Explanation for Shorting Stocks <!--ViewCount:ArticleHistoryID=21443681&PostDate=2018-7-16&type=m&id=483133--></p> <p style= Insider Buying and Selling by Sol Gel Technologies Quarter (NASDAQ: SLGL)

Receive News & Ratings for Sol Daily Gel Technologies – concise daily summary of the latest news and badysts' ratings for Sol Gel Technologies and related companies MarketBeat.com's FREE daily email newsletter. [19659011] [ad_2]
Source link

Tags

Powered by https://naaju.com/israel | Designed by Naaju
© Copyright 2024, All Rights Reserved